Biotech

Chinese flag
#AI #Antibody drug conjugate (ADC) #Biotech #China #ICON

China becoming dominant force in biotech sector, survey says 

China is emerging as a ‘global innovation powerhouse’, according to clinical research organisation ICON.  ICON’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.  According to the survey, funding remains a key challenge, with… Read More

#Business & Investment #News

#Biotech #Laboratoires Théa #Opthalmology

Biotech partnership to advance retinal drug pipeline 

Biotechnology company Iolyx Therapeutics has entered a strategic development and commercialisation agreement with ophthalmic specialty company Laboratoires Théa to advance its retinal pipeline.  Under the license and development agreement, Iolyx has granted Théa exclusive worldwide development and commercialisation rights, excluding Asia, to ILYX-002 for the treatment of ocular surface diseases.   Iolyx will receive up to… Read More

#Business & Investment #News

#Biotech #Financing #TRIMTECH Therapeutics

TRIMTECH Therapeutics appoints new Chair of the Board 

Biotechnology company TRIMTECH Therapeutics has appointed Alison Lawton as Chair of the Board as the company moves to advance its portfolio of disease-modifying therapies.  Lawton arrives at TRIMTECH with more than 35 years of global pharma and biotech leadership expertise, leading global regulatory strategy for numerous product approvals and gaining extensive… Read More

#News

Quantum computing
#Artificial intelligence (AI) #Biotech #Life sciences #Quantum computing

Quantum-biotech partnership to develop next-gen therapeutics  

Quantum company IonQ has partnered with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate next-generation therapeutics using hybrid quantum and quantum-AI technologies.  The collaboration will initially focus on areas including bioprocess optimisation, disease-modelling workflows, and quantum-enhanced simulation to support the design and manufacturing of advanced therapies. By bringing together CCRM’s expertise in… Read More

#Business & Investment #News

Diffuse large B-cell lymphoma
#Acute Myeloid Leukaemia #Biotech #CAR-T #Lymphoma

Imviva to present data on CAR-T pipeline 

Biotechnology company Imviva Biotech is set to present data on its CAR-T pipeline at the American Society of Haematology (ASH) Annual Meeting.  Imviva will reveal progress in allogeneic cell therapy candidates being developed for multiple haematological conditions, including T-cell acute lymphoblastic leukaemia, lymphoblastic lymphoma, acute myeloid leukaemia, B-cell… Read More

#Cancer Research #News

#Biotech #Europe #Investment #Start-ups #Venture funds

European biotech venture funds raise over €1.1 billion

Two European biotech venture funds have raised over €1.1 billion in capital in the last week.  Sofinnova Partners announced the close of Sofinnova Capital XI at €650 million, while Medicxi closed its Medicxi V fund at €500 million.  Sofinnova Capital XI attracted strong support from a global base of blue-chip… Read More

#Business & Investment #Editor's Choice #News #Start-up Zone

T cell therapy in lupus
#Biotech #Business #Cell therapy

Cue Biopharma and ImmunoScape partner on cell therapies 

Biotechnology companies Cue Biopharma and ImmunoScape have entered into a collaboration and license agreement to advance cell therapies for the treatment of solid tumours.  Under the agreement, ImmunoScape will develop a novel ‘Seed-and-Boost’ immunotherapy that combines Cue Biopharma’s clinically-validated Immuno-STAT T-cell engagers with ImmunoScape’s proprietary TCRs. The combination therapy is designed to overcome core limitations of existing cell therapies with the potential… Read More

#Business & Investment #News

Structure of the eye
#Biotech #Financing #Stargardt disease

AAVantgarde Bio raises $141 million for IRD trials

Biotechnology company AAVantgarde Bio has raised $141 million to advance its clinical programmes in inherited retinal disorders (IRD) Stargardt disease and Usher 1B syndrome.  The investment follows a successful Series B financing round, led by Schroders Capital and existing investors Atlas Venture and Forbion.   AAVantgarde aims to use the proceeds to complete the clinical study of AAVB-039… Read More

#Business & Investment #News

Leukaemia
#Acute Myeloid Leukaemia #Biotech #European Medicines Agency

Ipsen acquires ImCheck Therapeutics for AML treatment

Pharmaceutical company Ipsen is set to purchase French biotechnology company ImCheck Therapeutics to develop acute myeloid leukaemia (AML) treatment ICT01.  ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer, which received Orphan Drug Designations from the US Food and Drug Administration and European… Read More

#Business & Investment #News

The tumour microenvironment
#Biotech #Cancer research #Tumours

Iksuda Therapeutics reveals positive data from IKS014 trial

Biotechnology company Iksuda Therapeutics has announced positive data from the Phase I study of IKS014 for the treatment of cancer patients with advanced HER2+ solid tumours.  IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, resulted in anti-tumour activity across all dose levels in various tumour… Read More

#News

Osteoarthritis
#Arthritis #Biotech #Clinical trial

Elevara Medicines raises $70 million for RA Phase II trial

Biotechnology company Elevara Medicines has raised $70 million in Series A financing to advance its Phase II rheumatoid arthritis (RA) trial and pipeline.  The Series A proceeds, co-led by Forbion and Sofinnova Partners, will support Elevara’s upcoming Phase II clinical trial of its lead candidate ELV001. The investment will also… Read More

#Business & Investment #News

#Antimicrobial resistance (AMR) #Biotech #Vaccines

A universal approach to vaccines 

DDW Editor Reece Armstrong speaks to Dr Neil Murray, CEO of Liverpool-based RenewVax, that is developing the first universal vaccine for invasive pneumococcal disease, as well as vaccines for other antimicrobial resistant bacterial infections.   RA: What’s the current unmet need in terms of preventing and treating pneumococcal disease?   NM:… Read More

#Exclusive Content

#Biotech #CDMO #Collaboration #Drug development

How speed and clarity decide biotech’s winners 

Dr Thomas Meins, General Manager of WuXi AppTec’s subsidiary Crelux in Munich, Germany discusses how agile collaboration helps innovators adapt and succeed. Every biotech project begins with a vision, an idea with the potential to turn science into impact. But a vision alone is not enough. Turning that idea into… Read More

#Exclusive Content

Haematology
#Biotech #Financing #Haematology #Immunology

Star Therapeutics announces $125 million financing for VWD therapy

Biotechnology company Star Therapeutics has announced its $125 million Series D financing round was oversubscribed and will now initiate a clinical trial of its von Willebrand disease (VWD) therapy.  The financing round was co-led by Sanofi Ventures and Viking Global Investors, with participation from both… Read More

#News

European biotech
#Biologics / Biotechnology #Biotech #Europe #European Commission #European Union

Is the European Biotech Act a one-shot solution for the biotech sector?

For European Biotech Week, Diana Turner and Dr Claire Skentelbery, Director General, EuropaBio, examine the potential impact of the European Biotech Act. The European Biotech Act was first introduced by Ursula von der Leyen in 2024 in her paper ‘Europe’s Choice: Political Guidelines For The Next European Commission 2024−2029’. She… Read More

#Exclusive Content #Trends & Analysis